H. Scott Baldwin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
H. Scott Baldwin has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Xianghu Qu
Department of Pediatrics (Cardiology), Vanderbilt University Medical Center, Nashville, TN, United States
5 shared publicationsBin Zhou
Department of Genetics, Albert Einstein College of Medicine, NY 10461, USA
2 shared publicationsEric M. Graham
Medical University of South Carolina
2 shared publicationsKel Vin Woo
Department of Pediatrics, Division of Cardiology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
2 shared publications- Kevin D. Hill
Duke University Medical Center
2 shared publications Kevin L. Tompkins
Vanderbilt University School of Medicine 3 Department of Pediatrics Nashville, TN 37232
2 shared publications
Latest Publications
- 27 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (5)
TIE2 links MEKK3–KLF2/4 and PI3K signaling in cerebral cavernous malformation
Cerebral cavernous malformations (CCMs) are vascular lesions in the central nervous system that can cause strokes and seizures. Aggressive CCM growth follows an endothelial cell two-hit mechanism in which enhanced MEKK3–KLF2/4 signaling stimulates PI3K signaling, but how these pathways are linked has been undefined. Here, we use human CCM specimens, two mouse models of CCM disease, and primary human endothelial cells to examine the roles of the major endothelial growth factor receptors, VEGFR2 and TIE2. We find no evidence of augmented VEGFR2 signaling in CCM lesions, and neither genetic nor pharmacologic blockade of VEGFR2 reduced CCM formation in mouse models. Instead, we observe markedly increased phospho-TIE2 levels in human and mouse CCM lesions, MEKK3–KLF2/4-driven induction of TIE2 receptor expression, and almost complete rescue of CCM formation following genetic or pharmacologic TIE2 blockade in mouse models. Our studies identify TIE2 as the molecular link between the MEKK3–KLF2/4 and PI3K signaling pathways during CCM formation and suggest that targeting TIE2 may be an effective means to treat human CCM disease.
- 27 March 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (5)
TIE2 links MEKK3–KLF2/4 and PI3K signaling in cerebral cavernous malformation
Cerebral cavernous malformations (CCMs) are vascular lesions in the central nervous system that can cause strokes and seizures. Aggressive CCM growth follows an endothelial cell two-hit mechanism in which enhanced MEKK3–KLF2/4 signaling stimulates PI3K signaling, but how these pathways are linked has been undefined. Here, we use human CCM specimens, two mouse models of CCM disease, and primary human endothelial cells to examine the roles of the major endothelial growth factor receptors, VEGFR2 and TIE2. We find no evidence of augmented VEGFR2 signaling in CCM lesions, and neither genetic nor pharmacologic blockade of VEGFR2 reduced CCM formation in mouse models. Instead, we observe markedly increased phospho-TIE2 levels in human and mouse CCM lesions, MEKK3–KLF2/4-driven induction of TIE2 receptor expression, and almost complete rescue of CCM formation following genetic or pharmacologic TIE2 blockade in mouse models. Our studies identify TIE2 as the molecular link between the MEKK3–KLF2/4 and PI3K signaling pathways during CCM formation and suggest that targeting TIE2 may be an effective means to treat human CCM disease.
- Open Access
A Bayesian Re-analysis of the Steroids to Reduce Systemic Inflammation after Infant Heart Surgery (STRESS) Trial
Background Prophylactic steroids are often used to reduce the systemic inflammatory response to cardiopulmonary bypass in infants undergoing heart surgery. The STRESS trial found that the likelihood of a worse outcome did not differ between infants randomized to methylprednisolone (n=599) versus placebo (n=601) in a risk-adjusted primary analysis (adjusted odds ratio [OR], 0.86; 95% CI, 0.71 to 1.05; P=0.14). However, secondary analyses showed possible benefits with methylprednisolone. To ensure that a potentially efficacious therapy is not unnecessarily avoided, we re-analyzed the STRESS trial using Bayesian analytics to assess the probability of benefit. Methods Our Bayesian analysis used the original STRESS trial primary outcome measure, a hierarchically ranked composite of death, transplant, major complications and post-operative length of stay. We evaluated probability of benefit (OR1) by comparing the posterior distribution of the OR assuming a neutral probability of benefit versus harm with weak prior belief strength (nearly non-informative prior distribution). Reference results were calculated under the vague prior distribution. To convey magnitude of effect we used model parameters to calculate a predicted risk of death, transplant or major complications for methylprednisolone and placebo. Analyses consisted of 10 Markov Chain Monte Carlo simulations, each consisting of 2000 iterations with a 1000 iteration burn-in to ensure proper posterior convergence. Sensitivity analyses evaluated pessimistic (5%-30% prior likelihood of benefit), neutral and optimistic (70%-95%) prior beliefs, and controlled strength of prior belief as weak (30% variance), moderate (15%) and strong (5%). Results In primary analysis, the posterior probability of benefit from methylprednisolone was 91% and probability of harm was 9%. Composite death or major complication occurred in 18.8% of trial subjects with an absolute risk difference of -2% (95% CI -3%, +1%) associated with methylprednisolone. Each of 9 sensitivity analyses demonstrated greater probability of benefit than harm in the methylprednisolone group with 8 of 9 demonstrating >80% probability of benefit and ≥1% absolute difference in risk of death, transplant or major complications. Conclusion Probability of benefit with prophylactic methylprednisolone is high and harm is unlikely. This more in-depth analysis of the data expands the initial clinical evaluation of methylprednisolone provided by the STRESS trial.
Open AccessA Bayesian Re-analysis of the Steroids to Reduce Systemic Inflammation after Infant Heart Surgery (STRESS) Trial
Background Prophylactic steroids are often used to reduce the systemic inflammatory response to cardiopulmonary bypass in infants undergoing heart surgery. The STRESS trial found that the likelihood of a worse outcome did not differ between infants randomized to methylprednisolone (n=599) versus placebo (n=601) in a risk-adjusted primary analysis (adjusted odds ratio [OR], 0.86; 95% CI, 0.71 to 1.05; P=0.14). However, secondary analyses showed possible benefits with methylprednisolone. To ensure that a potentially efficacious therapy is not unnecessarily avoided, we re-analyzed the STRESS trial using Bayesian analytics to assess the probability of benefit. Methods Our Bayesian analysis used the original STRESS trial primary outcome measure, a hierarchically ranked composite of death, transplant, major complications and post-operative length of stay. We evaluated probability of benefit (OR1) by comparing the posterior distribution of the OR assuming a neutral probability of benefit versus harm with weak prior belief strength (nearly non-informative prior distribution). Reference results were calculated under the vague prior distribution. To convey magnitude of effect we used model parameters to calculate a predicted risk of death, transplant or major complications for methylprednisolone and placebo. Analyses consisted of 10 Markov Chain Monte Carlo simulations, each consisting of 2000 iterations with a 1000 iteration burn-in to ensure proper posterior convergence. Sensitivity analyses evaluated pessimistic (5%-30% prior likelihood of benefit), neutral and optimistic (70%-95%) prior beliefs, and controlled strength of prior belief as weak (30% variance), moderate (15%) and strong (5%). Results In primary analysis, the posterior probability of benefit from methylprednisolone was 91% and probability of harm was 9%. Composite death or major complication occurred in 18.8% of trial subjects with an absolute risk difference of -2% (95% CI -3%, +1%) associated with methylprednisolone. Each of 9 sensitivity analyses demonstrated greater probability of benefit than harm in the methylprednisolone group with 8 of 9 demonstrating >80% probability of benefit and ≥1% absolute difference in risk of death, transplant or major complications. Conclusion Probability of benefit with prophylactic methylprednisolone is high and harm is unlikely. This more in-depth analysis of the data expands the initial clinical evaluation of methylprednisolone provided by the STRESS trial.
- Open Access
- 9 January 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 38, 101257
Evaluating registry-based trial economics: Results from the STRESS clinical trial
- 9 January 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 38, 101257
Open AccessEvaluating registry-based trial economics: Results from the STRESS clinical trial
- 7 February 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (3) , e027993
Genetic Variants Associated With Systolic Blood Pressure in Children and Adolescents
Background: Genetics, along with lifestyle and behavioral characteristics, play an important role in hypertension in adults. Our aim was to identify genetic variants associated with blood pressure in childhood and adolescence. Methods and Results: We conducted a candidate single‐nucleotide polymorphism (SNP) analysis and genome‐wide association study among 9778 participants aged Z score. Analyses were conducted in the overall cohort and stratified by age group. A polygenic risk score was calculated for each participant, and the association between polygenic risk score and median SBP percentile in childhood was examined using linear regression. In the overall candidate SNP analysis, 2 SNPs reached significance: rs1018148 ( FBN1 ; P =1.0×10 –4 ) and rs11105354 ( ATP2B1 ; P =1.4×10 –4 ). In the postpuberty age group, 1 SNP reached significance: rs1018148 ( FBN1 ; P =2.2×10 –5 ). In the genome‐wide association study of all participants, no SNPs reached genome‐wide significance. Higher polygenic risk score was associated with higher SBP percentile (β, 0.35 [95% CI, 0.10–0.60)], and there was a significant interaction with age ( P for interaction<0.01). Conclusions: These findings suggest that genetic variants play an important role in SBP in childhood and adolescence and provide evidence for age‐specific genetic associations with SBP.
- 7 February 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (3) , e027993
Genetic Variants Associated With Systolic Blood Pressure in Children and Adolescents
Background: Genetics, along with lifestyle and behavioral characteristics, play an important role in hypertension in adults. Our aim was to identify genetic variants associated with blood pressure in childhood and adolescence. Methods and Results: We conducted a candidate single‐nucleotide polymorphism (SNP) analysis and genome‐wide association study among 9778 participants aged Z score. Analyses were conducted in the overall cohort and stratified by age group. A polygenic risk score was calculated for each participant, and the association between polygenic risk score and median SBP percentile in childhood was examined using linear regression. In the overall candidate SNP analysis, 2 SNPs reached significance: rs1018148 ( FBN1 ; P =1.0×10 –4 ) and rs11105354 ( ATP2B1 ; P =1.4×10 –4 ). In the postpuberty age group, 1 SNP reached significance: rs1018148 ( FBN1 ; P =2.2×10 –5 ). In the genome‐wide association study of all participants, no SNPs reached genome‐wide significance. Higher polygenic risk score was associated with higher SBP percentile (β, 0.35 [95% CI, 0.10–0.60)], and there was a significant interaction with age ( P for interaction<0.01). Conclusions: These findings suggest that genetic variants play an important role in SBP in childhood and adolescence and provide evidence for age‐specific genetic associations with SBP.
- Open Access
- 4 May 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 857581
Endocardial-Myocardial Interactions During Early Cardiac Differentiation and Trabeculation
Throughout the continuum of heart formation, myocardial growth and differentiation occurs in concert with the development of a specialized population of endothelial cells lining the cardiac lumen, the endocardium. Once the endocardial cells are specified, they are in close juxtaposition to the cardiomyocytes, which facilitates communication between the two cell types that has been proven to be critical for both early cardiac development and later myocardial function. Endocardial cues orchestrate cardiomyocyte proliferation, survival, and organization. Additionally, the endocardium enables oxygenated blood to reach the cardiomyocytes. Cardiomyocytes, in turn, secrete factors that promote endocardial growth and function. As misregulation of this delicate and complex endocardial-myocardial interplay can result in congenital heart defects, further delineation of underlying genetic and molecular factors involved in cardiac paracrine signaling will be vital in the development of therapies to promote cardiac homeostasis and regeneration. Herein, we highlight the latest research that has advanced the elucidation of endocardial-myocardial interactions in early cardiac morphogenesis, including endocardial and myocardial crosstalk necessary for cellular differentiation and tissue remodeling during trabeculation, as well as signaling critical for endocardial growth during trabeculation.
- 4 May 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 857581
Open AccessEndocardial-Myocardial Interactions During Early Cardiac Differentiation and Trabeculation
Throughout the continuum of heart formation, myocardial growth and differentiation occurs in concert with the development of a specialized population of endothelial cells lining the cardiac lumen, the endocardium. Once the endocardial cells are specified, they are in close juxtaposition to the cardiomyocytes, which facilitates communication between the two cell types that has been proven to be critical for both early cardiac development and later myocardial function. Endocardial cues orchestrate cardiomyocyte proliferation, survival, and organization. Additionally, the endocardium enables oxygenated blood to reach the cardiomyocytes. Cardiomyocytes, in turn, secrete factors that promote endocardial growth and function. As misregulation of this delicate and complex endocardial-myocardial interplay can result in congenital heart defects, further delineation of underlying genetic and molecular factors involved in cardiac paracrine signaling will be vital in the development of therapies to promote cardiac homeostasis and regeneration. Herein, we highlight the latest research that has advanced the elucidation of endocardial-myocardial interactions in early cardiac morphogenesis, including endocardial and myocardial crosstalk necessary for cellular differentiation and tissue remodeling during trabeculation, as well as signaling critical for endocardial growth during trabeculation.
- Open Access
- 29 February 2020
- Published by Springer Nature
- p. 297-300
Perspective for Part IV
The advances that have been made in understanding the developmental processes and molecular pathways that control cardiac development have been enormous in the last several decades. It was the original goal of the first Takao Symposia in 1978 to promote the scientific understanding of cardiac morphogenesis to form a foundation for investigating the mechanisms of congenital heart disease. However, even the ambitious investigators who attended that first meeting would not have anticipated the rapid progress that has occurred in this field. Furthermore, few would have predicted that there would be serious discussion about exploiting developmental paradigms to promote cardiac stem cell differentiation as an approach to attain cardiac regeneration. In this section we get a glimpse of some exciting new developments in these areas that have been the direct result of insights presented at and encouraged by the Takao Symposia.
- 29 February 2020
- Published by Springer Nature
- p. 297-300
Open AccessPerspective for Part IV
The advances that have been made in understanding the developmental processes and molecular pathways that control cardiac development have been enormous in the last several decades. It was the original goal of the first Takao Symposia in 1978 to promote the scientific understanding of cardiac morphogenesis to form a foundation for investigating the mechanisms of congenital heart disease. However, even the ambitious investigators who attended that first meeting would not have anticipated the rapid progress that has occurred in this field. Furthermore, few would have predicted that there would be serious discussion about exploiting developmental paradigms to promote cardiac stem cell differentiation as an approach to attain cardiac regeneration. In this section we get a glimpse of some exciting new developments in these areas that have been the direct result of insights presented at and encouraged by the Takao Symposia.
- Open Access
- 11 July 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (13)
Tie2 regulates endocardial sprouting and myocardial trabeculation
The ang1-tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2) pathway is required for normal vascular development, but its molecular effectors are not well-defined during cardiac ontogeny. Here, we show that endocardial-specific attenuation of Tie2 results in midgestation lethality due to heart defects associated with a hyperplastic but simplified trabecular meshwork (fewer but thicker trabeculae). Reduced proliferation and production of endocardial cells following endocardial loss of Tie2 results in decreased endocardial sprouting required for trabecular assembly and extension. The hyperplastic trabeculae result from enhanced proliferation of trabecular cardiomyocytes, which is associated with upregulation of bone morphogenetic protein 10, increased retinoic acid (RA) signaling, and extracellular signal-regulated protein kinases 1 and 2 hyperphosphorylation in the myocardium. Intriguingly, myocardial phenotypes in conditional knockout hearts could be partially rescued by inhibiting in utero RA signaling with pan-RA receptor antagonist BMS493. These findings reveal 2 complementary functions of endocardial Tie2 during ventricular chamber formation: ensuring normal trabeculation by supporting endocardial cell proliferation and sprouting and preventing hypertrabeculation via suppression of RA signaling in trabecular cardiomyocytes.
- 11 July 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (13)
Open AccessTie2 regulates endocardial sprouting and myocardial trabeculation
The ang1-tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2) pathway is required for normal vascular development, but its molecular effectors are not well-defined during cardiac ontogeny. Here, we show that endocardial-specific attenuation of Tie2 results in midgestation lethality due to heart defects associated with a hyperplastic but simplified trabecular meshwork (fewer but thicker trabeculae). Reduced proliferation and production of endocardial cells following endocardial loss of Tie2 results in decreased endocardial sprouting required for trabecular assembly and extension. The hyperplastic trabeculae result from enhanced proliferation of trabecular cardiomyocytes, which is associated with upregulation of bone morphogenetic protein 10, increased retinoic acid (RA) signaling, and extracellular signal-regulated protein kinases 1 and 2 hyperphosphorylation in the myocardium. Intriguingly, myocardial phenotypes in conditional knockout hearts could be partially rescued by inhibiting in utero RA signaling with pan-RA receptor antagonist BMS493. These findings reveal 2 complementary functions of endocardial Tie2 during ventricular chamber formation: ensuring normal trabeculation by supporting endocardial cell proliferation and sprouting and preventing hypertrabeculation via suppression of RA signaling in trabecular cardiomyocytes.
- Open Access
- 1 May 2019
- Published by The Company of Biologists in Development
- Vol. 146 (9)
Myocardial differentiation is dependent upon endocardial signaling during early cardiogenesis in vitro
The endocardium interacts with the myocardium to promote proliferation and morphogenesis during the later stages of heart development. However, the role of the endocardium in early cardiac ontogeny remains under-explored. Given the shared origin, subsequent juxtaposition, and essential cell-cell interactions of endocardial and myocardial cells throughout heart development, we hypothesized that paracrine signaling from the endocardium to the myocardium is crucial for initiating early differentiation of myocardial cells. To test this, we generated an in vitro, endocardial-specific ablation model using the diphtheria toxin receptor under the regulatory elements of the Nfatc1 genomic locus (NFATc1-DTR). Early treatment of NFATc1-DTR mouse embryoid bodies with diphtheria toxin efficiently ablated endocardial cells, which significantly attenuated the percentage of beating EBs in culture and expression of early and late myocardial differentiation markers. The addition of Bmp2 during endocardial ablation partially rescued myocyte differentiation, maturation and function. Therefore, we conclude that early stages of myocardial differentiation rely on endocardial paracrine signaling mediated in part by Bmp2. Our findings provide novel insight into early endocardial-myocardial interactions that can be explored to promote early myocardial development and growth.
- 1 May 2019
- Published by The Company of Biologists in Development
- Vol. 146 (9)
Open AccessMyocardial differentiation is dependent upon endocardial signaling during early cardiogenesis in vitro
The endocardium interacts with the myocardium to promote proliferation and morphogenesis during the later stages of heart development. However, the role of the endocardium in early cardiac ontogeny remains under-explored. Given the shared origin, subsequent juxtaposition, and essential cell-cell interactions of endocardial and myocardial cells throughout heart development, we hypothesized that paracrine signaling from the endocardium to the myocardium is crucial for initiating early differentiation of myocardial cells. To test this, we generated an in vitro, endocardial-specific ablation model using the diphtheria toxin receptor under the regulatory elements of the Nfatc1 genomic locus (NFATc1-DTR). Early treatment of NFATc1-DTR mouse embryoid bodies with diphtheria toxin efficiently ablated endocardial cells, which significantly attenuated the percentage of beating EBs in culture and expression of early and late myocardial differentiation markers. The addition of Bmp2 during endocardial ablation partially rescued myocyte differentiation, maturation and function. Therefore, we conclude that early stages of myocardial differentiation rely on endocardial paracrine signaling mediated in part by Bmp2. Our findings provide novel insight into early endocardial-myocardial interactions that can be explored to promote early myocardial development and growth.
- 14 September 2018
- Published by Elsevier
Specification of Cardiac Progenitors During Development
- 30 January 2018
- Published by Wolters Kluwer Health in Circulation
- Vol. 137 (5) , 504-507
Lymphangiogenesis in Chronic Rejection and Coronary Allograft Vasculopathy
- 30 January 2018
- Published by Wolters Kluwer Health in Circulation
- Vol. 137 (5) , 504-507
Lymphangiogenesis in Chronic Rejection and Coronary Allograft Vasculopathy